Urologic oncologists who treat prostate cancer are split over the benefits of focal therapy compared to traditional surgery ...
Surveillance has surged for favorable-risk prostate cancer, but focal therapy remains in use despite limited evidence and ...
TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...
Researchers developed an approach to treating prostate cancer, successfully eliminating cancerous cells in 73% of patients in the study. Prostate cancer is the second leading cause of cancer death ...
MedPage Today on MSN
Study questions how prostate cancer focal therapy is being used
Half of procedures occurred in settings not supported by guidelines ...
— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Francis Medical's Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug Administration (FDA). Vanquish is a transurethral, ultrasound and ...
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
Prostate cancer is the second leading cause of cancer death among American men. A recent study, conducted by researchers from the University of Virginia, Mount Sinai, the University of Michigan, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results